Literature DB >> 2384606

Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat.

R W Davies1, I Staprans, F N Hutchison, G A Kaysen.   

Abstract

It has been established previously that nephrotic hyperlipidemia is characterized by both an increase in lipid synthesis and a defect in removal of lipoproteins. The relationship between these defects and altered albumin metabolism is uncertain. One hypothesis is that hepatic lipogenesis increases in parallel with albumin synthesis. To test this hypothesis, albumin synthesis was increased in nephrotic rats fed an 8.5% protein diet (LPN) by increasing dietary protein to 40% (HPN). Proteinuria was modulated in half of the rats fed 40% protein by enalapril (HPE). Albumin synthesis was the same in both HPN and HPE, but proteinuria was reduced in HPE compared to HPN, and so were serum cholesterol and triglycerides (TG). To examine the effect of serum albumin on lipid clearance in the absence of proteinuria, plasma clearance of chylomicrons (CM) and VLDL was measured in Nagase analbuminemic rats (NAR) and found to be no different than in normal SD rats. When proteinuria was induced in NAR and in SD rats, a severe and identical defect in both CM and VLDL clearance was acquired in both groups and blood lipid levels were increased to a similar degree in both groups. Neither hyperlipidemia nor defective removal of lipoproteins from the circulation are linked to albumin synthesis or serum albumin concentration but result, at least in part, from proteinuria. Postheparin lipoprotein lipase (LPL) activity was reduced slightly in nephrotic animals compared to nonnephrotic controls, but the most striking finding was a highly significant decrease in postheraprin LPL activity in normal NAR compared to SD rats (P less than 0.001), suggesting that reduced LPL activity is not responsible for reduced clearance of CM and VLDL in nephrotic rats.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384606      PMCID: PMC296766          DOI: 10.1172/JCI114750

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Studies on the synthesis and secretion of serum lipoproteins by rat liver slices.

Authors:  C M RADDING; D STEINBERG
Journal:  J Clin Invest       Date:  1960-10       Impact factor: 14.808

2.  A colloid osmometer for small fluid samples.

Authors:  K Aukland; H M Johnsen
Journal:  Acta Physiol Scand       Date:  1974-02

Review 3.  Lipoprotein metabolism in experimental nephrosis.

Authors:  J B Marsh
Journal:  J Lipid Res       Date:  1984-12-15       Impact factor: 5.922

4.  Albumin-deficient rat mutant.

Authors:  S Nagase; K Shimamune; S Shumiya
Journal:  Science       Date:  1979-08-10       Impact factor: 47.728

5.  Electron microscopic and biochemical study of lipoprotein synthesis in the isolated perfused rat liver.

Authors:  A L Jones; N B Ruderman; M G Herrera
Journal:  J Lipid Res       Date:  1967-09       Impact factor: 5.922

6.  Albumin homeostasis in the nephrotic rat: nutritional considerations.

Authors:  G A Kaysen; W G Kirkpatrick; W G Couser
Journal:  Am J Physiol       Date:  1984-07

7.  Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal?

Authors:  M K Chan; J W Persaud; L Ramdial; Z Varghese; P Sweny; J F Moorhead
Journal:  Clin Chim Acta       Date:  1981-12-24       Impact factor: 3.786

8.  Evidence for a new cause of defective plasma removal of very low density lipoproteins in insulin-deficient rats.

Authors:  H Bar-On; Y D Chen; G M Reaven
Journal:  Diabetes       Date:  1981-06       Impact factor: 9.461

9.  Hypertriacylglycerolemia and adipose tissue lipoprotein lipase activity in the Nagase analbuminemic rat.

Authors:  H Kikuchi; S Tamura; S Nagase; S Tsuiki
Journal:  Biochim Biophys Acta       Date:  1983-04-28

10.  Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats.

Authors:  I Staprans; J M Felts; W G Couser
Journal:  Metabolism       Date:  1987-05       Impact factor: 8.694

View more
  8 in total

Review 1.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 2.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

3.  The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1.

Authors:  M Zaiou; N Azrolan; T Hayek; H Wang; L Wu; M Haghpassand; B Cizman; M P Madaio; J Milbrandt; J B Marsh; J L Breslow; E A Fisher
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 4.  Hyperlipidemia in childhood nephrotic syndrome.

Authors:  M A Thabet; J R Salcedo; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

5.  Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.

Authors:  Seungyeup Han; Nosratola D Vaziri; Pavan Gollapudi; Vincent Kwok; Hamid Moradi
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

6.  Lack of plasma albumin impairs intravascular lipolysis and explains the associated free fatty acids deficiency and hypertriglyceridemia.

Authors:  Tiago R Figueira; Aníbal E Vercesi; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2010-12-27       Impact factor: 3.876

7.  Albumin is an interface between blood plasma and cell membrane, and not just a sponge.

Authors:  Jens van de Wouw; Jaap A Joles
Journal:  Clin Kidney J       Date:  2021-10-05

8.  Effect of Lovastatin on lipid peroxidation and total antioxidant concentrations in hemodialysis patients.

Authors:  Hassan Argani; Amir Ghorbani; Nadereh Rashtchizade; Mohammad Rahbaninobar
Journal:  Lipids Health Dis       Date:  2004-04-22       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.